In a twist on new uses of old things, Arthramid® Vet is a unique and patented 2.5% cross-linked polyacrylamide hydrogel
(PAAG) for intra-articular injection, and the first PAAG in the world registered for veterinary use. This revolutionary
hydrogel contains no active pharmaceutical ingredient and is highly effective, safe and long-lasting. It has been used
previously as a dermal filler in cosmetic surgery but early indications are this new application could one day even
prevent joint damage.
Arthramid® Vet is injected into the joint of animals where it integrates into the joint capsule of the diseased joint to
provide a biocompatible tissue scaffold into which the body’s own tissues grow. This increases the elasticity, strength
and stability of the joint resulting in reduced pain and lameness and improved joint function. The first negative
effects of arthritis seen in a diseased joint.
The final parts of the research conducted in NZ and Australia were led by two NZ veterinarians and included
collaboration with Otago University and local labs to understand the mechanism of action and safety of the product. The
product, produced under license in Denmark, is now registered for use in horses in Australia and NZ and signals a move
away from anti inflammatories for managing this debilitating disease.
Furthermore, with the welfare of animals, and particularly race horses, becoming a major focus for industry groups the
potential to reduce the use of corticosteroids is another significant benefit.